FasTCAR-T GC012F nunjukkeun tingkat réspon 100% sadayana dina sababaraha myeloma anu nembe didiagnosis

Introduction Even in transplant-eligible (TE) patients, typical first-line treatments for high-risk (HR) newly-diagnosed multiple myeloma (NDMM) have dismal outcomes. A high-efficacy, safe CAR-T treatment could address this large..

Pangobatan Anu Ngarobah Kahirupan pikeun Kanker Darah Tungtungna Kakeunaan!

Kanker getih mangrupikeun jinis kanker anu mangaruhan getih sareng sumsum tulang. Éta mangrupikeun jinis kanker anu paling umum kalima di dunya, kalayan sakitar 1.24 juta kasus anyar didiagnosis unggal taun. Naha kanker getih tiasa diubaran? Fin..

NMPA Approves FUCASO: Multiple Myeloma Treatment Di Cina

Laju réspon sakabéh terapi kanker revolusioner ieu ngaranna FUCASO nyaéta 96%. Persetujuan NMPA nandaan titik balik dina perang Cina ngalawan sababaraha myeloma. Blog ieu ngajalajah efektivitas terapi ieu, s..

Pangobatan Kanker Gratis Di Cina Tanpa Ngarecah Bank: Pitunjuk Pikeun Anu Pangbutuhna

Free cancer treatment in China is providing hope and healing to people in need. So, if you are unable to opt for cancer treatment because of its extensive cost, this guide is specially meant for you. Find out how reputed organiz..

Pituduh Informatif Ngeunaan Tanda Berbisik Sareng Gejala Multiple Myeloma

Read our guide to learn about the silent indicators of multiple myeloma. Learn to spot them early, so you can make smart choices for your health. Don't ignore the warning signs, empower yourself with knowledge and take charge..

Titingalian Langkung Deukeut Rupa-rupa Tahapan Multiple Myeloma

Learn about the different stages and types of multiple myeloma. Find hope and support with information on treatments and coping strategies. This simple guide can help you take charge of your health and fight against multiple myel..

Cina, India

Kumaha Pencitraan Diagnostik Nyalametkeun Kahirupan di Multiple Myeloma Battles?

Panasaran kumaha téknik médis nyalametkeun nyawa sababaraha pasien myeloma? Baca blog urang pikeun leuwih jéntré ngeunaan téknik nyalametkeun kahirupan ieu! Hayu urang balikkeun halaman ngeunaan kanker babarengan. Carita harepan anjeun dimimitian di dieu. naraka..

BCMA, Elranatamab-bcmm, sababaraha myeloma

Elranatamab-bcmm nampi persetujuan gancangan ku FDA pikeun sababaraha myeloma

Nov 2023: Elranatamab-bcmm (Elrexfio, Pfizer, Inc.) is a bispecific B-cell maturation antigen (BCMA)-directed CD3 T-cell engager that was given accelerated approval by the Food and Drug Administration for adults with relapsed or ..

Janssen Biotéh, MonumenTAL-1, sababaraha myeloma, Talquetamab-tgvs, Talvey

Talquetamab-tgvs parantos nampi persetujuan gancangan pikeun sababaraha myeloma kambuh atanapi refractory.

Agustus 2023: Talquetamab-tgvs (Talvey, Janssen Biotech, Inc.) parantos dibéré persetujuan gancangan ku Administrasi Pangan sareng Narkoba pikeun pengobatan déwasa sareng sababaraha myeloma kambuh atanapi refractory anu parantos ngalaman di ..

Uji coba terapi CAR T Cell, sababaraha percobaan myeloma

Percobaan klinis dina terapi sél CAR-T pikeun penderita BCMA / TACI-positip kambuh sareng / atanapi sababaraha myeloma refractory.

Ringkesan Ringkesan: Hiji studi ngeunaan terapi sél APRIL CAR-T pikeun penderita BCMA / TACI positif kambuh jeung / atawa refractory multiple myeloma Katerangan Detil: Ieu panangan tunggal, buka-label, single-puseur stu..